Issue of Equity

RNS Number : 9380D

Avacta Group PLC

30 October 2015

 



30 October 2015

Avacta Group plc

("Avacta", the "Company" or the "Group")

Issue of Equity

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, today announces that 489,914 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by former employees.

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 3 November 2015.

The total number of Ordinary Shares in issue following the above issue will be 6,741,139,464 each with voting rights.  No Ordinary Shares are held in Treasury.

The above figure of 6,741,139,464 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

- Ends -

For further information:

Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer	Tel:  [phone] www.avacta.com
Numis Securities Limited     Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking	Tel:  [phone] www.numiscorp.com
Media Enquiries FTI Consulting Simon Conway/Natalie Garland-Collins	Tel: [phone] [e-mail]

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. The Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. The Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well as several partnered development programmes. Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers and via a growing on-line catalogue of Affimer reagents.

 

END

 

 

IOEUKAWRVAARUAA